Loading...

Events & Presentations

Upcoming Events

There are currently no events to display.

Presentations

Documents Date
Characterization of Exudative AMD in the OAKS and DERBY Phase 3 Trials of Pegcetacoplan for Geographic Atrophy
June 10, 2022
Efficacy of Pegcetacoplan in Subgroups Defined by Distance from the Foveal Center Point in the Phase 3 OAKS and DERBY studies of Patients with Geographic Atrophy
June 10, 2022
Geographic Atrophy Lesion Growth in Pegcetacoplan-treated Study Eyes Versus Untreated Fellow Eyes in Patients with Bilateral GA in the OAKS, DERBY, and FILLY Trial
June 10, 2022
First Quarter 2022 Earnings Presentation
May 4, 2022
Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 18-month results from the phase 3 OAKS and DERBY studies
May 2, 2022
Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of Geographic Atrophy (GA): A Post-hoc Analysis of OAKS, DERBY, and FILLY
May 2, 2022
Results of a Delphi Consensus Study of Geographic Atrophy (GA) Diagnosis and Current Management
May 2, 2022
Apellis 18 Month Analysis of DERBY and OAKS Ph3 Studies
March 16, 2022
Fourth Quarter 2021 Earnings Presentation
February 28, 2022
40th Annual J.P. Morgan Healthcare Conference Presentation
January 10, 2022
Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 PRINCE Study
December 13, 2021
Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter
December 13, 2021
Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration With Pegcetacoplan: Updates on the Randomized Phase 3 DERBY and OAKS Trials
November 12, 2021
Third Quarter 2021 Earnings Presentation
November 8, 2021
Safety of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials
October 11, 2021
Efficacy of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials
October 11, 2021
Safety of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials
September 30, 2021
Efficacy of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials
September 30, 2021
Apellis DERBY and OAKS Phase 3 Top-Line Results Conference Call Presentation
September 9, 2021
Second Quarter 2021 Earnings Presentation
August 9, 2021
Apellis R&D Day Presentation
June 30, 2021
Apellis EMPAVELI FDA Approval Conference Call Presentation
May 17, 2021
First Quarter 2021 Earnings Presentation
April 28, 2021
Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) Presentation
January 28, 2021
39th Annual J.P. Morgan Healthcare Conference Presentation
January 12, 2021
Jefferies Virtual London Healthcare Conference Call Presentation
November 19, 2020
COVID-19 Study Updates
October 15, 2020
PEGASUS Phase 3 Top-Line Results Conference Call Presentation
January 7, 2020

Past Events

Print Page Email Alerts RSS Feeds Contact IR